# Amedisys Inc. (AMED)

**Exchange:** NASDAQ  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-28  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/AMED/primer

## Business Model

---
source: coverage-next-full
ticker: AMED
step: 01
title: Business Model
retrieved: 2026-05-28
---

### Step 01 — Business Model: Amedisys, Inc.

#### Key Findings

- AMED was a **three-segment post-acute and in-home healthcare services operator**: Home Health (~70% revenue), Hospice (~25%), and High Acuity Care via Contessa Health (~5%) [S1].
- The business is **labor-intensive services**, not asset-intensive — clinical labor (RNs, LPNs, therapists, home health aides) is the dominant cost (60-70% of revenue). CapEx is negligible (~0.3% of revenue) [S2].
- Reimbursement is **dominated by Medicare** (75-80% of revenue [S1]), with Medicare Advantage and Medicaid making up most of the balance. Direct-pay/commercial is immaterial.
- **Net direction:** business model is fundamentally sound but rate-setting-exposed; the value-chain layer is execution-driven service delivery with limited pricing power.

#### Implications for Thesis and Valuation

1. **Operating leverage is moderate.** Clinical labor scales near-linearly with patient volume; back-office and overhead deliver the leverage.
2. **Goodwill-heavy balance sheet** (FY2023: $1.25B goodwill vs. $1.07B equity [S2]) reflects the M&A-fueled scale strategy. ROIC analysis (Step 09) must adjust for this.
3. **CMS rate-setting is the single largest exogenous variable** for forward modeling — discussed in Step 11.
4. **High Acuity Care (Contessa)** is the only segment with materially different unit economics (per-episode bundled payments vs. PDGM episode-based), and was loss-making through FY2024.

#### Objective

Map the AMED business model, value-chain position, and segment economics; identify what kind of company this is for downstream framework selection.

#### Narrative Analysis

Amedisys's business model is conceptually simple: it employs clinicians who deliver healthcare services in patients' homes, and bills government and commercial payers for those visits. The complexity is operational — managing thousands of clinicians across hundreds of metro areas, optimizing route density and visit productivity, maintaining compliance with extensive Medicare regulations, and recruiting/retaining clinical talent in a chronically tight labor market [S1].

**Home Health (~70% of revenue, ~$1.65B at FY2024 run-rate).** The largest and most mature segment. Home health agencies provide skilled nursing, physical/occupational/speech therapy, and home health aide services to patients recovering from acute episodes (typically post-hospital discharge for elderly patients with chronic conditions). Medicare pays under PDGM, which since 2020 uses a 30-day episodic payment with case-mix adjustment by clinical group, functional impairment level, timing (early vs. late), referral source, and comorbidity adjustment [S3]. AMED averaged ~340 care centers in 36 states by FY2024 [S1].

**Hospice (~25% of revenue, ~$580M at FY2024 run-rate).** End-of-life care for patients certified terminally ill (life expectancy ≤6 months under two consecutive certifications). Medicare pays four per-diem rates by service intensity (Routine Home Care, Continuous Home Care, Inpatient Respite, General Inpatient). Length of stay and per-beneficiary caps limit revenue accumulation at extreme tail lengths. AMED operated ~165 hospice care centers in 33 states [S1].

**High Acuity Care (~$30-50M revenue, growing but loss-making).** Acquired via the 2021 Contessa Health purchase, this segment delivers hospital-at-home and SNF-at-home services through joint-venture partnerships with health systems. Reimbursement model differs materially — bundled per-episode payments under CMS waiver authority (Acute Hospital Care at Home program extended through 2026) and JV revenue shares with hospital partners [S1]. Segment has been investment-mode loss-making but is strategically important for value-based-care alignment.

**Personal Care segment was divested in 2023** for ~$50M; this was a non-clinical adult-day-care / personal-assistance business that did not fit the clinical post-acute focus [S4].

The value-chain position is "service delivery layer" — between (1) the referral source (hospitals, SNFs, physicians, MA plans), (2) the payer (Medicare/MA/Medicaid), and (3) the patient/family. AMED captures value by efficiently matching clinicians to patient need, maintaining quality scores (CMS HHCAHPS, Star ratings) to win referral and payer preference, and optimizing per-clinician productivity. Pricing power is essentially zero on the Medicare side (rate is fixed by CMS) and limited on MA contracts (small carriers' worse leverage compounded by limited alternative provider availability gives some terms negotiation room).

#### Evidence and Sources

- Segment structure and care-center counts [S1]: 10-K FY2024
- Revenue concentration by payer mix [S1]: 10-K FY2024 (~75-80% Medicare)
- CapEx as % of revenue (FY2017-2024): consistently 0.3-0.5% per XBRL data [S2]
- Personal Care divestiture detail [S4]: 10-K FY2023
- PDGM methodology references [S3] (CMS rules)

#### Assumption Register Updates

- A04 (Estimate, refined): Medicare share of revenue = 75-80% (10-K disclosures)

#### Tables and Calculations

##### Value-Chain Layer Map

| Layer | Player | AMED's Role | Pricing Power |
|-------|--------|------------|---------------|
| Payer | CMS (Medicare FFS), MA plans, Medicaid, Commercial | n/a (counterparty) | None for AMED |
| Care management | MA plans, ACOs, MSSP entities | Sometimes contracted partner | Limited |
| Referral source | Hospitals (discharge planning), SNFs, physicians, MA care managers | Network partner — relationship-driven | Limited |
| **Service delivery (AMED's layer)** | **Home health agencies, hospice operators** | **Direct clinical delivery in patient home** | **Operational efficiency only** |
| Patient | n/a (recipient) | Customer experience drives retention/referrals | n/a |

##### Segment Snapshot (FY2024 estimates from 10-K segment notes)

| Segment | Revenue ($M) | Share | Operating Margin (est) | Notes |
|---------|-------------:|------:|----------------------:|-------|
| Home Health | ~1,650 | 70% | ~7-9% | PDGM-paid; largest segment |
| Hospice | ~580 | 25% | ~10-15% | Per-diem; higher margin |
| High Acuity (Contessa) | ~50 | 2% | (loss) | Investment mode |
| Other / Corporate | ~70 | 3% | (overhead) | Allocated central costs |
| **Total** | **2,348** | 100% | **4.0% (GAAP, depressed)** | FY2024 actual [S2] |

#### Open Questions and Data Gaps

- Exact segment-level operating income disclosed only in 10-K segment notes (Note 16); estimates above synthesize from filing context
- High Acuity profitability trajectory beyond FY2024 — moot now given closing
- Medicare Advantage vs. Medicare FFS revenue split not separately disclosed in detail

#### Next-Step Dependencies

Step 02 will use the segment mix and reimbursement structure to size the addressable markets. Step 03 will use this segment breakdown for the revenue architecture deep dive.

#### Source Index

| Source Tag | Document or URL | Section / Page | Date |
|-----------|---------------|-----------------|------|
| S1 | 10-K FY2024 | Business section, Item 1; segment note | 2025-02-27 |
| S2 | SEC XBRL companyfacts | CIK 0000896262 | 2026-05-28 |
| S3 | CMS PDGM rules | cms.gov | 2024-2025 |
| S4 | 10-K FY2023 | Personal Care divestiture note | 2024-02-22 |

## Financial Snapshot

---
source: coverage-next-full
ticker: AMED
step: 04
title: Financial Quality
retrieved: 2026-05-28
---

### Step 04 — Financial Quality + Adversarial Sweep

#### Key Findings

- **Accounting quality is generally clean.** AMED audited by KPMG; no restatements, no material weaknesses disclosed in FY2024 [S1]. Goodwill is large ($1.25B at FY23 [S2]) but periodic impairment testing has been transparent — FY2023 included a ~$46M hospice-related goodwill impairment [S3].
- **FY2023 net loss of $9.7M** was driven by the **$106M Option Care Health (OPCH) merger termination fee** and additional hospice impairments, both clearly disclosed; FY2024 returned to GAAP profitability ($43.2M net income) [S2][S3].
- **Cash conversion is strong.** FCF / Net income ratio averaged >1.5× over FY2017-2024; CapEx ~0.3% of revenue [S2].
- **No active SEC investigation or restatement.** Hospice GIP audits (2022-2023) affected revenue recognition for a portion of inpatient-tier days, but were resolved without enforcement action [S3].
- **Net direction:** financial quality is solid — clean accounting, strong cash conversion, conservative auditor; one-time items in FY2023-2024 distort margins but are well-disclosed.

#### Implications for Thesis and Valuation

1. **Normalized profitability framework is reliable** — adjusting for OPCH termination fee, hospice goodwill impairment, and merger-related costs gives a normalized FY2023 op margin of ~9-10% and FY2024 of ~7-8%.
2. **FCF is the better profit metric than GAAP earnings** for AMED, given goodwill drag on reported net income vs. cash-generative operating model.
3. **No "off-balance-sheet" surprises** identified — capital structure, lease obligations (operating leases for care centers), and goodwill are all on-balance-sheet and transparent.

#### Objective

Assess accounting quality, identify one-time / non-recurring items, examine GAAP-vs-economic earnings reconciliation, and conduct an adversarial research sweep for any short reports, lawsuits, or investigations.

#### Narrative Analysis

AMED's financial statements have been audited by **KPMG LLP** continuously for many years [S1]. The most recent 10-K (FY2024) contains an unqualified audit opinion. **Critical Audit Matters (CAMs)** disclosed include:
1. Goodwill impairment testing — given AMED's $1.25B+ goodwill balance, KPMG identifies this as a CAM each year, involving estimates of segment fair value
2. Revenue recognition for Medicare/Medicaid — given complex PDGM and hospice per-diem rules

Neither CAM disclosure indicates a quality concern; both reflect inherent complexity in the business model and have been consistent CAMs for the industry.

**One-time / non-recurring items in the recent years:**

1. **FY2022:** Hospice GIP revenue audit reserves recorded; modest restatement of certain hospice revenue. The 2022 10-K disclosed this transparently [synthesized from public discussion].
2. **FY2023:** $106M OPCH merger termination fee paid in June 2023 and recorded in operating expenses [S3]. This single line item explains why operating income dropped from $251.9M in FY21 to $156.4M in FY23, and net income flipped to $(9.7)M [S2]. Additionally, ~$46M of hospice goodwill was impaired [S3].
3. **FY2024:** Implied Q4 operating loss (FY total minus 9M reported) suggests continued merger-related professional fees, divestiture-prep costs, and possibly conservative reserve-building ahead of the close. Q1 2025 immediately bounced back to $43.4M operating income [S2], confirming the FY24 charges were episodic.

**Normalized profitability bridge:**

| Year | GAAP Op Inc ($M) | Adjustment ($M) | Normalized Op Inc ($M) | Normalized Margin |
|------|------------------:|----------------:|------------------------:|------------------:|
| 2021 | 251.9 | — | 251.9 | 11.4% |
| 2022 | 180.8 | +20 (GIP reserves) | 200.8 | 9.0% |
| 2023 | 156.4 | +152 (OPCH fee + impairments) | 308.4 | 13.8%* |
| 2024 | 94.5 | +85 (merger costs + Q4 charges) | 179.5 | 7.6% |

*FY23 "normalized" estimate may overstate underlying margin if hospice audit dynamics absorbed real economic value; treat with caution.

The economic operating margin clearly normalizes in the 7-10% range, with peak 2021 (11.4%) reflecting unusual COVID-era favorable conditions (delayed PDGM cuts, pandemic-related payer programs).

**Cash conversion is genuinely strong.** Over FY2018-2024, AMED generated $1.59B in cumulative CFO against ~$890M in cumulative GAAP net income — a 1.79× ratio [S2]. CapEx is trivial (~$45M cumulative over 7 years). The "real" earning power is more visible in FCF than in GAAP EPS.

#### Adversarial Research Sweep

The skill mandates an explicit adversarial sweep — looking for short reports, investigations, restatements, lawsuits, and reputational issues that could undermine the franchise. Findings for AMED:

| Item | Status | Notes |
|------|--------|-------|
| **Short-seller reports** | None identified | No major activist short reports (Hindenburg, Muddy Waters, Wolfpack, Citron, etc.) covering AMED in the 2020-2025 period [S5] |
| **SEC investigations** | None disclosed | No 12b-1 or formal investigation noted in any 10-K disclosures [S1][S3] |
| **Restatements** | Minor hospice GIP reserves in 2022-2023; no GAAP restatement | Disclosed transparently [S3] |
| **CMS / OIG audits** | Routine hospice GIP audits in 2022-2023 | Industry-wide; resolved without enforcement |
| **DOJ False Claims Act (FCA) settlements** | One historical settlement | AMED settled FCA matters relating to home-health certification practices in mid-2010s (~$150M settlement era); since then no major FCA action [S6] |
| **Securities class actions** | Routine merger-related lawsuits | Standard "Trulia"-style M&A challenges from plaintiff firms; resolved with supplemental disclosures [S4] |
| **Major reputational issues** | None | Clinical-quality issues at any large home-health operator can surface; no major scandal in recent period |
| **Auditor concerns** | None | KPMG continuous; CAMs are routine for the industry |

The mid-2010s FCA settlement is worth noting historically: in 2014, AMED paid $150M to settle False Claims Act allegations relating to home-health certifications and billing for ineligible patients (allegations dating to 2009-2011 period under prior management). Since the post-2014 turnaround under Paul Kusserow, the compliance posture has been substantially strengthened, and no material new FCA action has emerged.

**Conclusion:** financial quality is **clean** with well-disclosed episodic items. No adversarial red flags requiring further investigation.

#### Evidence and Sources

- Audit and CAM disclosures [S1]: 10-K FY2024, KPMG audit opinion
- Goodwill impairment and OPCH termination fee detail [S3]: 10-K FY2023
- FY2022 hospice GIP reserves [S2]: 10-K FY2022 and FY2023 disclosures
- Historical FCA settlement [S6]: DOJ press releases, public reporting (2014)
- Merger-related litigation [S4]: DEFM14A and 8-K disclosures

#### Assumption Register Updates

- A06 (Fact, confirmed): OPCH termination fee = $106M (2023)
- A20 (NEW, Estimate): Normalized FY24 op margin = ~7.6% (adjusted)
- A21 (NEW, Fact): No material short reports or SEC investigations identified

#### Tables and Calculations

##### Cash Conversion Quality (FY2017 – FY2024)

| Year | Net Income ($M) | CFO ($M) | FCF ($M) | CFO/NI | FCF/NI |
|------|----------------:|---------:|---------:|-------:|-------:|
| 2017 | n/a | 105.7 | 95.0 | n/a | n/a |
| 2018 | n/a | 223.5 | 216.9 | n/a | n/a |
| 2019 | 126.8 | 202.0 | 194.1 | 1.59× | 1.53× |
| 2020 | 183.6 | 289.0 | 283.6 | 1.57× | 1.54× |
| 2021 | 209.1 | 188.9 | 182.6 | 0.90× | 0.87× |
| 2022 | 118.6 | 133.3 | 127.1 | 1.12× | 1.07× |
| 2023 | (9.7) | 137.2 | 131.6 | n.m. | n.m. |
| 2024 | 43.2 | 221.7 | 215.1 | 5.13× | 4.98× |

##### Goodwill Roll-Forward (illustrative)

| Year-End | Goodwill ($M) | Notes |
|----------|-------------:|-------|
| 2016 | 289 | Pre-hospice growth |
| 2018 | 330 | |
| 2019 | 659 | Compassionate Care + Asana Hospice |
| 2020 | 933 | AseraCare acquisition (~$300M) |
| 2021 | 1,196 | Contessa acquisition (~$250M) |
| 2022 | 1,287 | Add-on activity |
| 2023 | 1,245 | -$46M impairment + other |
| 2024 | ~1,250 | Stable |

#### Open Questions and Data Gaps

- Detailed adjustments for FY24 Q4 not yet publicly enumerated (10-K FY24 has aggregate annual figures only)
- Forward goodwill testing under post-close ownership unknown (private now)

#### Next-Step Dependencies

Step 05 (Quarterly Momentum) and Step 06 (Balance Sheet) will use the normalized profitability framework above.

#### Source Index

| Source Tag | Document or URL | Section / Page | Date |
|-----------|---------------|-----------------|------|
| S1 | 10-K FY2024 | Audit opinion; CAMs | 2025-02-27 |
| S2 | SEC XBRL companyfacts | CIK 0000896262 | 2026-05-28 |
| S3 | 10-K FY2023 | OPCH termination, goodwill impairment | 2024-02-22 |
| S4 | DEFM14A | Merger litigation summary | 2023-08-10 |
| S5 | Short-interest databases (general knowledge) | n/a | 2026-05-28 |
| S6 | DOJ press release 2014 FCA settlement | justice.gov | 2014 |

## Recent Catalysts

---
source: coverage-next-full
ticker: AMED
step: 12
title: Bull vs Bear (Catalysts)
retrieved: 2026-05-28
---

### Step 12 — Bull vs. Bear (Analyst Debate Format)

> **Coverage note:** Coverage-next-full deliberately excludes earnings call transcripts. The bull/bear debate is constructed from filings, consensus notes, press releases, and prior public commentary. Without transcripts, the management-tone signals that inform a typical analyst-debate framing are inferred indirectly.

#### Key Findings

- AMED was **acquired by UnitedHealth Group (Optum) at $101.00/share cash, deal closed 2025-08-14**. The bull case won decisively as expressed in the deal close [S1].
- Pre-merger, the **bull case was anchored on (a) demographic tailwinds, (b) MA penetration driving home-care utilization, (c) acquisition-target optionality from managed-care buyers; **the **bear case was anchored on (a) CMS rate-setting risk, (b) labor inflation, (c) operating margin compression from acquisition goodwill drag**.
- **Net direction: ACQUIRED — bull case fulfilled by takeover.** Standalone forward debate is moot.

#### Implications for Thesis and Valuation

1. **The deal close at $101 validated** the takeover-target framing — a recurring theme in AMED research from 2018-2022 was that the company was a likely target for a managed-care vertical integrator.
2. **For remaining listed peers,** the same bull/bear framework applies. The bull case is reinforced by the consolidation precedent (deal multiples of ~14× EBITDA paid by strategic buyers). The bear case persists around CMS and labor.
3. **AMED-specific forward modeling is moot.** The retrospective debate is preserved for sector-comparison context.

#### Objective

Construct the structured bull-vs-bear debate for AMED at the moment of the merger announcement (May 2023) and through the deal close (August 2025). Use filings + consensus + press releases. End with explicit 3-bullet Bull Case and 3-bullet Bear Case for downstream consumption by `/complete-coverage` Step 15 and `/stocks/[ticker]` rendering.

#### Narrative Analysis

The pre-merger analyst debate on AMED (2020-2023) clustered around a few well-defined poles:

**Bull camp:** "AMED is one of the highest-quality public home-health operators with sector-leading clinical quality, scaled hospice, and an emerging High Acuity Care optionality via Contessa. Demographics drive volume; MA penetration drives utilization steering toward home. The franchise is a likely strategic target for managed-care vertical integrators (UNH, Humana, Aetna) — observed precedent: Humana's 2021-22 Kindred at Home acquisition, Optum's pending LHC Group deal. Target price $90-120 standalone DCF or $110-130 with takeout option."

**Bear camp:** "CMS PDGM behavioral assumption methodology creates structural rate headwind; labor inflation is eroding operating margin; the acquired-growth strategy via hospice rollups and Contessa is loading the balance sheet with goodwill that has not yet earned its cost of capital. Operating margin will compress from 11% (2021 peak) toward 6-7% (post-acquisitions, normalized). Standalone DCF $60-80; takeout optionality is real but speculative."

**The OPCH announcement (May 2022)** moved the debate. The OPCH all-stock deal was viewed by many analysts as below-fair-value — OPCH equity was less liquid and lower-quality, and the implied exchange ratio gave AMED holders less upside than a strategic-cash takeout would deliver. Several analyst-side commentary advocated for AMED to seek a topping bid.

**The UNH/Optum topping bid at $101 cash (May 2023)** confirmed the bull camp's "strategic target" framing. Compared to the OPCH all-stock implied value at the time of announcement (~$70-85/share equivalent depending on OPCH price assumption), the UNH bid at $101 was a clear win. Most analyst rating distributions moved to neutral/hold at deal-close-adjusted price targets near $101.

**The 24-month deal pendency (2023-2025)** was uneventful from a thesis-direction perspective. The principal uncertainty was deal-close timing (DOJ Second Request, divestitures). Standalone fundamentals (Q1-Q2 2025) showed recovery and validated the underlying franchise quality.

**Post-close (August 2025):** thesis moot for the security; relevant only as a precedent for remaining peers.

#### Bull Case — 3 Bullets (mandatory final framing)

1. **Strategic takeover candidate validated:** AMED was a high-quality home-health and hospice franchise that managed-care acquirers (Optum/UNH) pursued to vertically integrate with Medicare Advantage. The $101 cash close validated the multi-year bull case. **Deal closed August 14, 2025 at ~1.5× EV/Revenue, ~14× EV/EBITDA.**
2. **Demographic and MA tailwinds were durable:** 75+ population growth + MA penetration above 50% of Medicare beneficiaries drove structural demand for home health and hospice services. AMED's clinical quality scores (4-star Star Ratings) and national scale were rare in the operator landscape.
3. **Operational franchise value was real:** Normalized operating margin in the 7-10% range with strong cash conversion (FCF/NI >1.5×) and capital-light economics meant the underlying business was high-quality. Q1-Q2 2025 confirmed the franchise was operating well into close.

#### Bear Case — 3 Bullets (mandatory final framing)

1. **CMS rate-setting risk was structural and persistent:** PDGM behavioral assumption methodology imposed -2.890% permanent cut in FY2024 plus continued temporary adjustments — limiting standalone operating-margin recovery. Forward Medicare rate environment remains uncertain for surviving peers.
2. **Labor inflation eroded the moat:** Peak 5-7% clinical wage inflation in 2022-2023 compressed operating margin from 11.4% (FY2021) to 4.0% GAAP (FY2024). Productivity gains and PDGM coding optimization only partially offset.
3. **Acquisition-driven ROIC erosion:** ~$1.25B of accumulated goodwill (FY2023) meant returns on incremental invested capital ran below the cost of capital — Contessa (High Acuity Care) was loss-making through FY2024 and partially impaired. Without strategic takeover, fair value would have been notably below the $101 cash close.

#### Evidence and Sources

- Deal timeline and close: SEC filings (8-K closing, 25-NSE delisting, 15-12G deregistration) [S1]
- Analyst debate framing: synthesized from public sell-side commentary 2020-2023 (without transcripts) [S2]
- OPCH bid context: DEFM14A [S3]
- Operating fundamentals: XBRL companyfacts [S4]

#### Assumption Register Updates

- A34 (NEW, Judgment): Pre-merger fair value range $80-$110 standalone; takeout option lifted upper bound
- A35 (NEW, Fact): Deal close August 14, 2025 validates strategic-target framing

#### Tables and Calculations

##### Bull/Bear Scoring (qualitative)

| Variable | Bull Read | Bear Read | Net |
|----------|-----------|-----------|-----|
| Demographics / volume | Strong tailwind | Modest contribution | Bull |
| CMS rate-setting | Modest moderation possible | Structural headwind | Bear |
| Labor inflation | Moderating | Margin-destructive | Tilt Bear (in 22-23); moderated by 24-25 |
| Acquisition economics | Strategic value | ROIC dilutive | Mixed |
| Strategic-target option | High likelihood | Idiosyncratic | Bull |
| Standalone valuation | DCF supports $90-110 | DCF supports $60-80 | Mixed |
| **OUTCOME** | **VALIDATED at $101 close** | Moot post-close | **Bull won via M&A** |

##### Catalysts Timeline (Historical)

| Date | Event | Direction |
|------|-------|-----------|
| 2022-05-04 | OPCH all-stock merger announced | Mixed (deal at modest premium) |
| 2023-05-03 | UNH/Optum topping bid $101 cash | Strong Bull |
| 2023-08-10 | DEFM14A filed | Confirms |
| 2023-09-29 | Shareholders approve | Confirms |
| 2024-06-28 | DOJ Second Request | Risk |
| 2025-04-23 | DOJ settlement / divestiture progress | De-risks |
| 2025-08-14 | Deal closes; delisted | Final Bull validation |

#### Open Questions and Data Gaps

- Without transcripts, fine-grained management-tone signals are missing — limits the conventional analyst-debate construction
- Post-close strategic execution under Optum unknowable from public data
- Future PDGM rule trajectory remains the dominant variable for surviving peers

#### Next-Step Dependencies

Step 16 (Variant Perception) examines what the market actually priced vs. what played out. Step 18 (Portfolio Fit) is moot for AMED but documented.

#### Source Index

| Source Tag | Document or URL | Section / Page | Date |
|-----------|---------------|-----------------|------|
| S1 | SEC EDGAR filings (8-K, 25-NSE, 15-12G) | data.sec.gov | August 2025 |
| S2 | Sell-side / press coverage 2020-2023 | various (public) | 2020-2023 |
| S3 | DEFM14A | tm2321414-3_defm14a.htm | 2023-08-10 |
| S4 | SEC XBRL companyfacts | CIK 0000896262 | 2026-05-28 |

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/amed
- Full research API: GET /api/v1/research/AMED/memo
- Coverage universe: /stocks